SRR22247242
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.370
- PANCREAS_BETA_CELLS+0.330
- SPERMATOGENESIS+0.270
- MYOGENESIS+0.240
- E2F_TARGETS+0.220
- HEDGEHOG_SIGNALING+0.200
- G2M_CHECKPOINT+0.180
- MITOTIC_SPINDLE+0.060
- MYC_TARGETS_V2+0.050
- APICAL_JUNCTION+0.010
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.590
- PROTEIN_SECRETION-0.580
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.420
- ADIPOGENESIS-0.410
- ALLOGRAFT_REJECTION-0.410
- INFLAMMATORY_RESPONSE-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- COMPLEMENT-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JT82QGXF | medulloblastoma | — | 0.927 |
| 2 | SRR6013518 | — | cohortSQ1 | 0.910 |
| 3 | BS_44A3ES23 | medulloblastoma | — | 0.905 |
| 4 | SRR4195643 | — | — | 0.904 |
| 5 | MNG459 | — | — | 0.898 |
| 6 | AUR-AFEA-TTM1-A-1-1-R-A742-41 | — | E | 0.893 |
| 7 | BS_JVW2JJ39 | high-grade glioma | — | 0.891 |
| 8 | SRR6013541 | — | cohortSQ1 | 0.890 |
| 9 | SRR8943030 | — | — | 0.889 |
| 10 | BS_4E1G7E3G | ATRT | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |